Healthtech Startups
17,200 companies tagged Healthtech, with their investors and founders.
0 investors
Tilray Brands is a cannabis company that produces and sells medical and adult/recreational cannabis products through brands such as Aphria, Broken Coast, Solei, Good Supply and Riff. It serves patients, caregivers, and recreational consumers primarily in Canada, with operations extending to the US and Europe.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
TNF Pharmaceuticals is a clinical-stage biopharma company developing therapies for autoimmune and inflammatory diseases, with lead candidates including MYMD-1, an oral TNF-alpha inhibitor, and Supera-CBD, a synthetic cannabidiol analog.
0 investors
Toetal Solutions is a medical device company operating in the foot and ankle (podiatric/orthopedic) space, backed by the Runway Healthcare portfolio. The team combines medical device operators and podiatric surgeons focused on lower extremity treatment.
0 investors
0 investors
Tonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.
0 investors
Topaz Bio develops therapeutics for skin diseases by engineering the skin microbiome using metagenomics and synthetic biology. The company targets the substantial patient population affected by skin conditions.
0 investors
0 investors
Toro Neurovascular develops endovascular stroke devices, including large-bore aspiration catheters featuring MicroFlex reinforcement-wire technology for treating ischemic stroke and large vessel occlusions. Its products are intended for physicians performing neurovascular thrombectomy procedures.
0 investors
0 investors
Tosk is a pharmaceutical company developing therapeutics for oncology, including approaches to reduce treatment-limiting side effects of cancer therapy, drawing on Drosophila-based drug discovery models. Its leadership and advisory board consist of pharmaceutical industry executives, cancer researchers, and clinical oncologists.
0 investors
0 investors
0 investors
0 investors
0 investors